This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

This invention provides compounds, compositions and methods for modulating the expression of human GST-π using RNA interference. The RNA interference molecules can be used in methods for preventing or treating diseases such as malignant tumor. Provided are a range of siRNA structures, having one or more of nucleotides being modified or chemically-modified. Advantageous structures include siRNAs with 2′-deoxy nucleotides located in the seed region, as well as other nucleotide modifications.

The present invention relates to a chemically modified oligonucleotide for use in site-directed A-to-I editing of a target RNA inside a cell with endogenous ADAR, comprising a sequence with a length of 11 to 100 nucleotides capable of binding to a target sequence in the target RNA, with a Central Base Triplet of 3 nucleotides with the central nucleotide opposite to the target adenosine in the target RNA, which is to be edited to an inosine, whereby the core sequence has the following Formula I:

##STR00001##

wherein Nu stands for a nucleotide having a sugar moiety which may be modified, the numbers below the nucleotide sequence designate the position of the nucleotides adjacent to the central nucleotide of the Central Base Triplet having the number 0 whereby the negative numbers designate the 5′ end and the positive number designate the 3′ end of the oligonucleotide and wherein a-j designate the nature of the linkage between the single nucleotides whereby at least linkages a, d, and e are phosphorothioate linkages and whereby at least 2 linkages are a phosphate linkage(s).

The present invention relates to a chemically modified oligonucleotide for use in site-directed A-to-I editing of a target RNA inside a cell with endogenous ADAR, comprising a sequence with a length of 11 to 100 nucleotides capable of binding to a target sequence in the target RNA, with a Central Base Triplet of 3 nucleotides with the central nucleotide opposite to the target adenosine in the target RNA, which is to be edited to an inosine, whereby the core sequence has the following Formula I:

##STR00001##

wherein Nu stands for a nucleotide having a sugar moiety which may be modified, the numbers below the nucleotide sequence designate the position of the nucleotides adjacent to the central nucleotide of the Central Base Triplet having the number 0 whereby the negative numbers designate the 5′ end and the positive number designate the 3′ end of the oligonucleotide and wherein a-j designate the nature of the linkage between the single nucleotides whereby at least linkages a, d, and e are phosphorothioate linkages and whereby at least 2 linkages are a phosphate linkage(s).

The present disclosure relates to compositions of oligonucleotide (e.g., SMAD7 antisense oligonucleotide diastereomers) and methods of manufacturing, assessing efficacy, and using the compositions.

Method and apparatus for obtaining range information associated with a target using light detection and ranging (LiDAR). An emitter transmits a set of pulses of electromagnetic radiation to illuminate a target. The set of pulses includes a pair of emitted pulses with different waveform characteristics, such as slightly different phases. A detector receives a reflected set of pulses from the target. The received set of pulses includes a pair of received pulses with corresponding different waveform characteristics. The detector determines the range information by decoding the received pulses, such as by calculating an average of the phase differential in the received pulses. In this way, a single stage detector can be used without the need for separate I/Q (in-phase and quadrature) channels. Phase chirping can be used so that each successive pair of pulses has a different phase difference. Other waveform characteristics can be used including frequency, amplitude, shape, etc.

Method and apparatus for obtaining range information associated with a target using light detection and ranging (LiDAR). An emitter transmits a set of pulses of electromagnetic radiation to illuminate a target. The set of pulses includes a pair of emitted pulses with different waveform characteristics, such as slightly different phases. A detector receives a reflected set of pulses from the target. The received set of pulses includes a pair of received pulses with corresponding different waveform characteristics. The detector determines the range information by decoding the received pulses, such as by calculating an average of the phase differential in the received pulses. In this way, a single stage detector can be used without the need for separate I/Q (in-phase and quadrature) channels. Phase chirping can be used so that each successive pair of pulses has a different phase difference. Other waveform characteristics can be used including frequency, amplitude, shape, etc.

The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

The invention relates generally to tRNA-based effector molecules having a non-naturally occurring modification and methods relating thereto.

The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5′ AUGn.sub.1GGUGKUn.sub.2n.sub.3RGGGHUGUKGGGn.sub.4Gn.sub.5CGACGCA 3′ [SEQ ID NO: 61], wherein n.sub.1 is U or dU, n.sub.2 is G or dG, n.sub.3 is A or dA, n.sub.4 is U or dU, n.sub.5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2′-deoxyribonucleotides.